Crucell Press releases Latest Press releases from Crucell in English en http://www.crucell.com/ Copyright (c)2005 Crucell http://blogs.law.harvard.edu/tech/rss Hugin - http://www.hugingroup.com/ webmaster@crucell.com webmaster@crucell.com ti., 17 aug. 2010 13:51:47 +0200 10 <![CDATA[Crucell N.V. ]]> http://www.huginonline.nl/CRXL/logo_NEW2.gif http://www.crucell.com 195 98 <![CDATA[Crucell Reports Record Revenues in Second Quarter 2010]]> PRESS RELEASE 
  

Crucell Reports Record Revenues in Second Quarter 2010
Total revenues and other operating income of €128.6 million, a 63% growth compared to the same period in 2009 (€78.7 million).
Strong sales of Quinvaxem® drive record second quarter revenues.
Operating profit of €13.1 million compared to €3.2 million in Q2 2009.
Net profit of €9.2 million compared to net loss of €1.8 million in Q2 2009.
Undiluted EPS of €0.11 compared to minus €0.03 in the same quarter of 20 (...)

]]> Tue, 17 Aug 2010 07:45:00 +0200 http://cws.huginonline.com/C/132631/PR/201008/1438262_5_6.html Crucell N.V. <![CDATA[Crucell to Release Second Quarter 2010 Results on Tuesday August 17, 2010]]> Leiden, the Netherlands (August 11, 2010) - Dutch biopharmaceutical company Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that it will release its financial results for the second quarter 2010 on Tuesday August 17, 2010 at 07:45 AM Central European Time (CET).

At 2:00 PM Central European Time (CET), Crucell's management will conduct a conference call, which will also be webcast. To participate in the conference call, please call one of the following telephone (...)

]]> Wed, 11 Aug 2010 13:00:00 +0200 http://cws.huginonline.com/C/132631/PR/201008/1437148_5_6.html Crucell N.V. <![CDATA[Crucell and Harvard (BIDMC) Join Forces with IAVI to Advance AdVac®-based AIDS Vaccine]]> Leiden, the Netherlands (August 11, 2010) - Dutch biopharmaceutical company Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announces its intention to participate in an international Phase I clinical trial in the United States and Africa of a combination of two AdVac®-based AIDS vaccine candidates, Ad26.ENVA.01 and Ad35-ENV, in healthy adults who are not infected with HIV. The clinical trial, which will be led by the International AIDS Vaccine Initiative (IAVI), represen (...)

]]> Wed, 11 Aug 2010 07:45:00 +0200 http://cws.huginonline.com/C/132631/PR/201008/1436935_5_6.html Crucell N.V. <![CDATA[Crucell Reaches Agreement with Sanofi Pasteur on Programs in the Field of Paediatric and Respiratory Vaccines]]> Leiden, the Netherlands (July 8, 2010) - Dutch biopharmaceutical company Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that Crucell and sanofi pasteur reached an agreement on a series of transactions to restructure their long standing partnership.

 

Crucell will waive its right to terminate an existing license agreement between Crucell Switzerland and sanofi pasteur's subsidiary Shantha Biotechnics Limited (Shantha) for the development of paediatric vacc (...)

]]> Thu, 8 Jul 2010 07:45:00 +0200 http://cws.huginonline.com/C/132631/PR/201007/1430266_5_6.html Crucell N.V. <![CDATA[Crucell Announces Start of Universal RSV Vaccine Program]]> Leiden, the Netherlands (June 24, 2010) - Dutch biopharmaceutical company Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced the start of a discovery program leading to the development and commercialization of a universal respiratory syncytial virus (RSV) vaccine. The RSV vaccine will be designed to prevent severe infections with the most common RSV strains in infants and the elderly. This discovery program is part of the existing strategic collaboration with Johnson (...)

]]> Thu, 24 Jun 2010 07:45:00 +0200 http://cws.huginonline.com/C/132631/PR/201006/1426680_5_6.html Crucell N.V. <![CDATA[Crucell 2010 Annual General Meeting of Shareholders 2009 Financial Statements Adopted; All Resolutions Approved]]> Leiden, The Netherlands (June 4, 2010) - Dutch biopharmaceutical company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that the Annual General Meeting of Shareholders (AGM) held today in Leiden adopted the 2009 financial statements. In addition, the AGM reappointed Mr. J.P. Oosterveld as member of the Supervisory Board; Mr. W. Burns, Mr. J. Shannon and Mr. G. Siber were appointed as new members of the Supervisory Board.

The shareholders of Crucell were represente (...)

]]> Fri, 4 Jun 2010 16:52:39 +0200 http://cws.huginonline.com/C/132631/PR/201006/1421808_5_6.html Crucell N.V. <![CDATA[Crucell Announces First Quarter 2010 Results]]> PRESS RELEASE

Crucell Announces First Quarter 2010 Results

Total revenues and other operating income of €65.7 million were lower compared to €73.7 million in Q109 due to phasing of shipments into Q210. Strong April sales of Quinvaxem® expected to drive very strong second quarter revenues.

R&D expenses increased 31% to €20.0 million. Operating loss of €4.3 million.

Net loss of €2.3 million. Undiluted EPS of minus €0.03.

 Quarter-end cash and short-term liquidities €382.7 million.

2010 guid (...)

]]> Tue, 11 May 2010 07:45:00 +0200 http://cws.huginonline.com/C/132631/PR/201005/1414456_5_6.html Crucell N.V. <![CDATA[Crucell and NIH Announce Start of Malaria Vaccine Trial in Burkina Faso]]> Tue, 11 May 2010 07:45:00 +0200 http://cws.huginonline.com/C/132631/PR/201005/1414437_5_6.html Crucell N.V. <![CDATA[Crucell Announces New Award of $110 Million for Paediatric Vaccine Quinvaxem® by UNICEF to Support Vaccination Programs in the Developing World]]> Thu, 6 May 2010 07:45:00 +0200 http://cws.huginonline.com/C/132631/PR/201005/1412155_5_6.html Crucell N.V. <![CDATA[Crucell to Release First Quarter 2010 Results on Tuesday May 11, 2010]]> Tue, 4 May 2010 13:00:00 +0200 http://cws.huginonline.com/C/132631/PR/201005/1411559_5_6.html Crucell N.V. <![CDATA[Aeras and Crucell Announce Start of Phase II TB study in South Africa]]> Wed, 14 Apr 2010 07:45:00 +0200 http://cws.huginonline.com/C/132631/PR/201004/1403203_5_6.html Crucell N.V. <![CDATA[Crucell Announces Release of 2009 Annual Report and Form 20-F]]> Wed, 7 Apr 2010 18:16:00 +0200 http://cws.huginonline.com/C/132631/PR/201004/1401129_5_6.html Crucell N.V. <![CDATA[Crucell Announces Collaboration with GlaxoSmithKline Biologicals on Second Generation Malaria Vaccine Candidate ]]> Tue, 6 Apr 2010 07:45:00 +0200 http://cws.huginonline.com/C/132631/PR/201004/1400552_5_6.html Crucell N.V. <![CDATA[Crucell's Supervisory Board Nominates Mr. W. Burns, Mr. J. Shannon and Mr. G. Siber as New Board Members]]> Mon, 15 Mar 2010 07:45:00 +0100 http://cws.huginonline.com/C/132631/PR/201003/1393719_5_6.html Crucell N.V. <![CDATA[Crucell Appoints Jerald Sadoff MD as Chief Medical Officer]]> Mon, 8 Mar 2010 07:45:00 +0100 http://cws.huginonline.com/C/132631/PR/201003/1391485_5_6.html Crucell N.V. <![CDATA[Crucell Announces Record Revenues and Profits for Full Year 2009]]> Tue, 9 Feb 2010 07:45:00 +0100 http://cws.huginonline.com/C/132631/PR/201002/1382900_5_6.html Crucell N.V. <![CDATA[Crucell launches global brand to reflect and reinforce its leading position in healthcare innovation]]> Mon, 16 Nov 2009 07:45:00 +0100 http://cws.huginonline.com/C/132631/PR/200911/1355022_5_6.html Crucell N.V. <![CDATA[Crucell Announces Third Quarter 2009 Results]]>
Operating profit of €15.5 million versus €9.6 million in Q3 2008.
Quarter-end cash and short-term liquidities of €411.9 million.
Undiluted EPS of €0.15 for the quarter.

2009 full year guidance reiterated: total revenues and other operating income expected to grow 20% in constant currencies ; operating profit for 2009 expected to improve significantly compared to 2008; strong cash position.]]> Tue, 3 Nov 2009 07:45:00 +0100 http://cws.huginonline.com/C/132631/PR/200911/1352094_5_6.html Crucell N.V. <![CDATA[Crucell HIV Vaccine: Promising Preliminary Results Phase I Study Presented by Dr Dan Barouch at AIDS Vaccine 2009 in Paris]]> Wed, 21 Oct 2009 12:30:00 +0200 http://cws.huginonline.com/C/132631/PR/200910/1348705_5_6.html Crucell N.V. <![CDATA[Crucell Rabies Monoclonal Antibody Combination: Positive Results Philippines Phase II Study Presented at RITA Conference]]> Tue, 20 Oct 2009 15:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200910/1348634_5_6.html Crucell N.V. <![CDATA[Crucell Strengthens its Vaccine Sales in the UK with a Dedicated Marketing and Sales Organization]]> Wed, 30 Sep 2009 07:45:00 +0200 http://cws.huginonline.com/C/132631/PR/200909/1344744_5_6.html Crucell N.V. <![CDATA[Johnson & Johnson and Crucell Announce Strategic Collaboration to Develop Innovative Products, Including Therapies for Influenza Prevention and Treatment]]>
]]> Mon, 28 Sep 2009 07:45:00 +0200 http://cws.huginonline.com/C/132631/PR/200909/1343928_5_6.html Crucell N.V. <![CDATA[Crucell Receives NIH Award for the Development of Influenza Monoclonal Antibodies]]> Tue, 18 Aug 2009 07:45:00 +0200 http://cws.huginonline.com/C/132631/PR/200908/1335383_5_6.html Crucell N.V. <![CDATA[New awards of $300 million for Quinvaxem® bringing total value up to $800 million]]> Mon, 17 Aug 2009 07:45:00 +0200 http://cws.huginonline.com/C/132631/PR/200908/1335043_5_6.html Crucell N.V. <![CDATA[Crucell Announces Second Quarter 2009 Results]]>
Gross margin 39%, up from 36% in Q2 2008.
Operating profit of €3.2 million versus operating loss of €9.0[1] million in Q2 2008.]]> Tue, 11 Aug 2009 07:44:00 +0200 http://cws.huginonline.com/C/132631/PR/200908/1333770_5_6.html Crucell N.V. <![CDATA[Crucell to Release Q2 2009 Results on Tuesday August 11, 2009]]> Tue, 4 Aug 2009 14:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200908/1332592_5_6.html Crucell N.V. <![CDATA[MVI and Crucell Announce Collaboration new Malaria Vaccine Approach]]> Wed, 29 Jul 2009 07:45:00 +0200 http://cws.huginonline.com/C/132631/PR/200907/1331245_5_6.html Crucell N.V. <![CDATA[Crucell Announces Positive Results of Phase II Clinical Study Rabies Monoclonal Antibody Combination in Philippines]]> Wed, 24 Jun 2009 07:45:00 +0200 http://cws.huginonline.com/C/132631/PR/200906/1324434_5_6.html Crucell N.V. <![CDATA[Crucell 2009 Annual General Meeting of Shareholders 2008 Financial Statements Adopted; All Resolutions Approved]]> Fri, 5 Jun 2009 16:37:37 +0200 http://cws.huginonline.com/C/132631/PR/200906/1320546_5_6.html Crucell N.V. <![CDATA[Crucell Announces First Quarter 2009 Results]]>
Total first quarter revenues and other operating income increased over 50% to €73.7 million, compared to €47.9 million in the same period of 2008.
Gross margin in the first quarter improved to 45% up from 40% in Q1 2008.
Break-even compared to a net loss of €9.0 million in Q1 2008.

2009 full year guidance reiterated: total revenues and other operating income expected to grow 20% in constant currencies ; operating profit for 2009 expected to improve significantly compared to 2008; solid cash flow.
]]> Wed, 6 May 2009 07:45:00 +0200 http://cws.huginonline.com/C/132631/PR/200905/1311542_5_6.html Crucell N.V. <![CDATA[Crucell to Release First Quarter 2009 Results on Wednesday, May 6, 2009]]> Wed, 29 Apr 2009 16:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200904/1309796_5_6.html Crucell N.V. <![CDATA[Aeras and Crucell Announce Start of TB Infant Study in South Africa]]> Tue, 28 Apr 2009 14:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200904/1308533_5_6.html Crucell N.V. <![CDATA[Crucell Announces Release 2008 Annual Report and Form 20-F]]> Fri, 24 Apr 2009 07:45:00 +0200 http://cws.huginonline.com/C/132631/PR/200904/1307812_5_6.html Crucell N.V. <![CDATA[Crucell's Revolutionary Antibody for Universal Therapy Against Flu]]> Thu, 26 Feb 2009 19:59:00 +0100 http://cws.huginonline.com/C/132631/PR/200902/1293663_5_6.html Crucell N.V. <![CDATA[DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6® Cell Line Proteins]]> Tue, 10 Feb 2009 07:44:00 +0100 http://cws.huginonline.com/C/132631/PR/200902/1288733_5_6.html Crucell N.V. <![CDATA[Crucell Announces Profits for Full Year 2008 ]]>
Total revenue and other operating income increased by 33% to €283.3 million compared to €213.1 million in 2007.
Positive cash flow of €7.7 million increased the year-end cash position to €171 million.
Gross margin for the year improved to 45% (from 34% last year).
]]> Thu, 5 Feb 2009 07:43:00 +0100 http://cws.huginonline.com/C/132631/PR/200902/1287572_5_6.html Crucell N.V. <![CDATA[Crucell to Release Q4 & FY 2008 Results on Thursday, February 5, 2009]]> Wed, 4 Feb 2009 22:28:00 +0100 http://cws.huginonline.com/C/132631/PR/200902/1287505_5_6.html Crucell N.V. <![CDATA[Discussions on a Combination of Crucell and Wyeth Discontinued]]> Mon, 26 Jan 2009 07:45:00 +0100 http://cws.huginonline.com/C/132631/PR/200901/1284766_5_6.html Crucell N.V. <![CDATA[Crucell and Wyeth in discussion on a combination of the two companies]]> Wed, 7 Jan 2009 22:35:00 +0100 http://cws.huginonline.com/C/132631/PR/200901/1280875_5_6.html Crucell N.V. <![CDATA[Crucell Announces STAR® Research and Commercial License Agreement with Centocor, Inc.]]> Tue, 6 Jan 2009 07:45:00 +0100 http://cws.huginonline.com/C/132631/PR/200901/1280377_5_6.html Crucell N.V. <![CDATA[DSM Biologics and Crucell Announce PER.C6® License Agreement with CSL Ltd.]]> Thu, 18 Dec 2008 14:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200812/1278298_5_6.html Crucell N.V. <![CDATA[DSM Biologics and Crucell Announce PER.C6® Research License Agreement with GSK]]> Thu, 18 Dec 2008 07:45:00 +0100 http://cws.huginonline.com/C/132631/PR/200812/1278291_5_6.html Crucell N.V. <![CDATA[Crucell Signs Second Exclusive License Agreement with Talecris Biotherapeutics]]> Wed, 17 Dec 2008 14:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200812/1278167_5_6.html Crucell N.V. <![CDATA[Crucell Announces Excellent Results for Influenza Antibody]]> Thu, 11 Dec 2008 07:45:00 +0100 http://cws.huginonline.com/C/132631/PR/200812/1276654_5_6.html Crucell N.V. <![CDATA[Crucell Announces Registration of Hepavax-Gene® in China]]> Mon, 8 Dec 2008 07:45:00 +0100 http://cws.huginonline.com/C/132631/PR/200812/1275474_5_6.html Crucell N.V. <![CDATA[DSM Biologics and Crucell Announce Commercial PER.C6® Licensing Agreement with Gedeon Richter]]> Tue, 25 Nov 2008 07:45:00 +0100 http://cws.huginonline.com/C/132631/PR/200811/1272380_5_6.html Crucell N.V. <![CDATA[Crucell Announces Third Quarter 2008 Results]]>
Crucell announces third quarter 2008 results with net income of €12.3 million.
Total revenue and other operating income increased by 31% to €82.1 million compared to the same quarter last year.
Gross margin in the third quarter mproved to 50% (from 36% last year).
2008 full year guidance for total revenue and other operating income growth increased to 25-30% in constant currencies (from 20%). ]]> Tue, 11 Nov 2008 07:45:00 +0100 http://cws.huginonline.com/C/132631/PR/200811/1268267_5_6.html Crucell N.V. <![CDATA[Crucell to Release Q3 2008 Earnings on Tuesday, November 11, 2008]]> Tue, 4 Nov 2008 14:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200811/1266175_5_6.html Crucell N.V. <![CDATA[Crucell Doubles Production of Quinvaxem® in 2008 and Prepares Move to New Korean Production Site to Facilitate Growth]]> Tue, 21 Oct 2008 12:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200810/1261549_5_6.html Crucell N.V. <![CDATA[Aeras and Crucell Announce TB Vaccine Clinical Trial in Kenya; Promising Vaccine Candidate Advances to Phase II Safety Study in South Africa]]> Fri, 17 Oct 2008 07:45:00 +0200 http://cws.huginonline.com/C/132631/PR/200810/1260403_5_6.html Crucell N.V. <![CDATA[Crucell Receives NIAID/NIH Contract for Development of Ebola and Marburg Vaccines]]> Fri, 3 Oct 2008 10:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200810/1256673_5_6.html Crucell N.V. <![CDATA[Crucell Announces Positive Results of Phase II Clinical Study Rabies Monoclonal Antibody Combination in US]]> Wed, 1 Oct 2008 21:30:00 +0200 http://cws.huginonline.com/C/132631/PR/200810/1256108_5_6.html Crucell N.V. <![CDATA[DSM and Crucell announce another key achievement for PER.C6® Technology; Scale up of high-titer Fed-Batch Process to 250 Liters]]> Mon, 29 Sep 2008 14:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200809/1255183_5_6.html Crucell N.V. <![CDATA[Crucell's Swiss Affiliate Berna Biotech to Cease All Animal Testing]]> Fri, 26 Sep 2008 07:45:00 +0200 http://cws.huginonline.com/C/132631/PR/200809/1254602_5_6.html Crucell N.V. <![CDATA[Lonza and Crucell enter into long term agreement]]> Thu, 25 Sep 2008 07:30:00 +0200 http://cws.huginonline.com/C/132631/PR/200809/1254212_5_6.html Crucell N.V. <![CDATA[New contracts awarded for Quinvaxem® and Hepavax-Gene®]]> Tue, 23 Sep 2008 07:45:00 +0200 http://cws.huginonline.com/C/132631/PR/200809/1253398_5_6.html Crucell N.V. <![CDATA[Crucell Signs Exclusive License Agreement with Talecris Biotherapeutics]]> Thu, 18 Sep 2008 07:45:00 +0200 http://cws.huginonline.com/C/132631/PR/200809/1252359_5_6.html Crucell N.V. <![CDATA[Crucell to move Dukoral® and rCTB bulk production, formulation and fill/finish activities from Sweden to other sites]]> Tue, 26 Aug 2008 14:45:00 +0200 http://cws.huginonline.com/C/132631/PR/200808/1246210_5_6.html Crucell N.V. <![CDATA[Crucell Announces Second Quarter 2008 Results]]>
Solid gross margins of 36% and significantly reduced net loss for the second quarter to €7.9 million compared to €18.2 million in Q207.
2008 full year guidance reiterated: total revenue and other operating income growth of 20% in constant currencies[1]; higher margins; positive cash flow.]]> Tue, 12 Aug 2008 07:45:00 +0200 http://cws.huginonline.com/C/132631/PR/200808/1242467_5_6.html Crucell N.V. <![CDATA[Crucell to Release Q2 2008 Earnings on Tuesday, August 12, 2008]]> Tue, 5 Aug 2008 14:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200808/1240767_5_6.html Crucell N.V. <![CDATA[DSM and Crucell Sign Agreement with Avid Bioservices to Serve as First Pre-Approved U.S. Contract Manufacturer of PER.C6® Cell Line Proteins]]> Wed, 25 Jun 2008 07:45:00 +0200 http://cws.huginonline.com/C/132631/PR/200806/1230793_5_6.html Crucell N.V. <![CDATA[DSM and Crucell Announce Record Achievement in PER.C6® Technology]]> Mon, 16 Jun 2008 08:15:00 +0200 http://cws.huginonline.com/C/132631/PR/200806/1227870_5_6.html Crucell N.V. <![CDATA[Crucell 2008 Annual General Meeting of Shareholders ]]>
]]> Fri, 30 May 2008 17:42:46 +0200 http://cws.huginonline.com/C/132631/PR/200805/1224024_5_6.html Crucell N.V. <![CDATA[Crucell Announces Research License Agreement with Bioceros on STAR® Technology]]> Tue, 20 May 2008 07:45:00 +0200 http://cws.huginonline.com/C/132631/PR/200805/1220482_5_6.html Crucell N.V. <![CDATA[Crucell Announces First Quarter 2008 Results]]>
Net loss in the quarter halved to €9.0 million compared to Q107.
New contracts awarded for Quinvaxem(TM) and strong sales
in travel vaccines drive autonomous growth.
Gross margin in the first quarter improved to 40% up from 23% last year.
2008 full year guidance reiterated: total revenue and other operating income growth of 20% in constant currencies ; higher margins; positive cash flow.]]> Tue, 13 May 2008 07:45:00 +0200 http://cws.huginonline.com/C/132631/PR/200805/1218450_5_6.html Crucell N.V. <![CDATA[Start of Phase II Clinical Study for Rabies Monoclonal Antibody Combination in the Philippines]]> Tue, 13 May 2008 07:45:00 +0200 http://cws.huginonline.com/C/132631/PR/200805/1218444_5_6.html Crucell N.V. <![CDATA[Crucell to Release Q1 2008 Earnings on Tuesday, May 13, 2008]]> Tue, 6 May 2008 07:45:00 +0200 http://cws.huginonline.com/C/132631/PR/200805/1215954_5_6.html Crucell N.V. <![CDATA[Crucell Announces STAR® Research License Agreement with Toyobo Gene Analysis Co. LTD.]]> Tue, 29 Apr 2008 07:45:00 +0200 http://cws.huginonline.com/C/132631/PR/200804/1214000_5_6.html Crucell N.V. <![CDATA[Aeras, Crucell and SATVI Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa]]> Wed, 9 Apr 2008 14:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200804/1207750_5_6.html Crucell N.V. <![CDATA[Crucell Announces STAR® Research License Agreement with Celltrion, Inc.]]> Tue, 8 Apr 2008 14:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200804/1207359_5_6.html Crucell N.V. <![CDATA[Crucell Announces First in Man Study with New Adenovirus Vector]]> Thu, 3 Apr 2008 14:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200804/1206104_5_6.html Crucell N.V. <![CDATA[Crucell Announces Start of Phase II Clinical Study Rabies Monoclonal Antibody Combination in US]]> Mon, 31 Mar 2008 14:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200803/1204647_5_6.html Crucell N.V. <![CDATA[Crucell Announces STAR® Research License Agreement with Medarex Inc]]> Tue, 25 Mar 2008 14:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200803/1203043_5_6.html Crucell N.V. <![CDATA[Crucell and DSM Biologics Announce Additional PER.C6® Licensing Agreement with MorphoSys]]> Mon, 17 Mar 2008 07:30:00 +0100 http://cws.huginonline.com/C/132631/PR/200803/1201280_5_6.html Crucell N.V. <![CDATA[Crucell Presents a Compelling Case for Investment at Investor and Analyst Day in London]]> Wed, 12 Mar 2008 10:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200803/1199681_5_6.html Crucell N.V. <![CDATA[DSM and Crucell Announce PER.C6® Technology Milestone]]> Tue, 11 Mar 2008 14:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200803/1199584_5_6.html Crucell N.V. <![CDATA[Crucell Announces Vaccine Development Agreement with Wyeth Pharmaceuticals]]> Mon, 3 Mar 2008 07:54:00 +0100 http://cws.huginonline.com/C/132631/PR/200803/1197206_5_6.html Crucell N.V. <![CDATA[Crucell Announces Fourth Quarter and Full Year 2007 Results]]>
€213.1 million, compared to €140.9 million in 2006.
Successful Quinvaxem(TM) launch drives strong autonomous growth.
Strong operating cash flow of €51.5 million in the fourth quarter and €22.2 million for the year compared to a negative €54.0 million in 2006.
2008 full year guidance: total revenue and other operating income growth of 20% in constant currencies ; higher margins; positive cash flow. ]]> Tue, 12 Feb 2008 07:45:00 +0100 http://cws.huginonline.com/C/132631/PR/200802/1190504_5_6.html Crucell N.V. <![CDATA[Crucell Nominates Cees de Jong as Management Board Member]]> Mon, 11 Feb 2008 14:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200802/1190334_5_6.html Crucell N.V. <![CDATA[Crucell to Release Q4/FY 2007 Earnings on Tuesday, February 12, 2008]]> Thu, 31 Jan 2008 07:45:00 +0100 http://cws.huginonline.com/C/132631/PR/200801/1186665_5_6.html Crucell N.V. <![CDATA[Crucell Nominates Steve Davis as Supervisory Board Member]]> Wed, 30 Jan 2008 14:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200801/1186560_5_6.html Crucell N.V. <![CDATA[Crucell Reacts to Recent CEVEC Press Release ]]> Wed, 16 Jan 2008 15:45:00 +0100 http://cws.huginonline.com/C/132631/PR/200801/1182706_5_6.html Crucell N.V. <![CDATA[Crucell Announces STAR® Technology Research License with Korean-based ISU ABXIS]]> Mon, 14 Jan 2008 14:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200801/1181827_5_6.html Crucell N.V. <![CDATA[TRADING UPDATE]]>
Operating cash flow increased to over €18 million.
Revenue and operating income for the year adjusted to €213 million.]]> Wed, 9 Jan 2008 11:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200801/1180573_5_6.html Crucell N.V. <![CDATA[Crucell Enters Agreement with Sanofi Pasteur for Next-generation Biologicals against Rabies]]> Thu, 3 Jan 2008 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200801/1179185_5_6.html Crucell N.V. <![CDATA[Aeras and Crucell Announce Start of a Tuberculosis Vaccine Clinical Trial in the United States. Aeras commits a further USD 5 million to the development of the tuberculosis vaccine]]> Fri, 21 Dec 2007 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200712/1178095_5_6.html Crucell N.V. <![CDATA[DSM Biologics and Crucell Announce PER.C6® Licensing Agreement with Medarex Inc.]]> Tue, 18 Dec 2007 14:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200712/1176995_5_6.html Crucell N.V. <![CDATA[Crucell Announces Research License Agreement with ProFibrix on STAR® Technology]]> Mon, 17 Dec 2007 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200712/1176383_5_6.html Crucell N.V. <![CDATA[Crucell Presents Indian Phase I Rabies Antibody Cocktail Study, Positive Results Enable Prompt Progression Towards Phase II Studies]]> Fri, 30 Nov 2007 09:30:00 +0100 http://cws.huginonline.com/C/132631/PR/200711/1171997_5_6.html Crucell N.V. <![CDATA[Crucell Announces PER.C6® Licensing Agreement with Acambis]]> Tue, 20 Nov 2007 14:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200711/1169702_5_6.html Crucell N.V. <![CDATA[DSM Biologics and Crucell Announce PER.C6® Licensing Agreement with Daiichi Sankyo Ltd.]]> Fri, 16 Nov 2007 14:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200711/1169014_5_6.html Crucell N.V. <![CDATA[Crucell Announces Third Quarter 2007 Results]]> Tue, 13 Nov 2007 08:34:37 +0100 http://cws.huginonline.com/C/132631/PR/200711/1167963_5_6.html Crucell N.V. <![CDATA[Crucell's Rabies Antibody Cocktail Granted Fast Track Status]]> Tue, 13 Nov 2007 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200711/1167833_5_6.html Crucell N.V. <![CDATA[Crucell Sells Stake in Pevion Biotech]]> Mon, 12 Nov 2007 14:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200711/1167732_5_6.html Crucell N.V. <![CDATA[Crucell Announces Marketing and Distribution Deal with Sanquin]]> Mon, 12 Nov 2007 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200711/1167644_5_6.html Crucell N.V. <![CDATA[Crucell to Release Q3 2007 Earnings on Tuesday, November 13, 2007]]> Tue, 6 Nov 2007 14:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200711/1166274_5_6.html Crucell N.V. <![CDATA[DSM Biologics and Crucell Announce PER.C6® Technology Licensing Agreement with Recepta Biopharma S.A.]]> Fri, 2 Nov 2007 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200711/1165479_5_6.html Crucell N.V. <![CDATA[Medimmune and Crucell announce collaboration to develop new antibodies for the treatment and prevention of hospital-acquired bacterial infection]]> Mon, 15 Oct 2007 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200710/1159796_5_6.html Crucell N.V. <![CDATA[Crucell presents Phase I results rabies antibody cocktail showing safety and ability to protect]]> Wed, 3 Oct 2007 16:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200710/1157795_5_6.html Crucell N.V. <![CDATA[Crucell discovers human monoclonal antibodies for the prevention and treatment of the avian flu virus. The antibody provides immediate protection and neutralizes the broadest range of H5N1 strains.]]> Thu, 27 Sep 2007 23:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200709/1156556_5_6.html Crucell N.V. <![CDATA[Impact of discontinuation of Merck HIV study on Crucell's prospects]]> Tue, 25 Sep 2007 14:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200709/1155850_5_6.html Crucell N.V. <![CDATA[Crucell to present pre-clinical results for H5N1 Virus treatment]]> Fri, 14 Sep 2007 12:04:02 +0200 http://cws.huginonline.com/C/132631/PR/200709/1153602_5_6.html Crucell N.V. <![CDATA[Crucell Appoints Mr. Cees de Jong as Chief Operating Officer]]> Mon, 10 Sep 2007 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200709/1152304_5_6.html Crucell N.V. <![CDATA[Crucell grants Merck & Co., Inc. access to vaccine technology]]> Mon, 10 Sep 2007 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200709/1152303_5_6.html Crucell N.V. <![CDATA[Crucell announces new STAR® technology research license in agreement with Invitrogen Corporation ]]> Thu, 6 Sep 2007 14:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200709/1151889_5_6.html Crucell N.V. <![CDATA[Crucell Announces Second Quarter 2007 Results]]> Tue, 14 Aug 2007 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200708/1146129_5_6.html Crucell N.V. <![CDATA[Crucell to Release Q2 2007 Earnings on Tuesday, August 14, 2007]]> Tue, 31 Jul 2007 14:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200707/1143052_5_6.html Crucell N.V. <![CDATA[Crucell Announces PER.C6® and AdVac® Technology License Agreement with Wyeth Pharmaceuticals]]> Mon, 30 Jul 2007 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200707/1142671_5_6.html Crucell N.V. <![CDATA[DSM Biologics and Crucell Announce PER.C6® Licensing Deal With LFB Biotechnologies.]]> Wed, 25 Jul 2007 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200707/1141554_5_6.html Crucell N.V. <![CDATA[Crucell announces Vaccine and Protein Business Unit Structure and Management Appointments]]> Wed, 18 Jul 2007 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200707/1140317_5_6.html Crucell N.V. <![CDATA[DSM Biologics and Crucell Announce PER.C6® Licensing Deal With Masterclone]]> Tue, 10 Jul 2007 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200707/1138332_5_6.html Crucell N.V. <![CDATA[Crucell CFO to present at two June Investor Conferences]]> Wed, 6 Jun 2007 14:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200706/1131470_5_6.html Crucell N.V. <![CDATA[DSM Biologics and Crucell Announce PER.C6® Licensing Deal With Sartorius Biotech GmbH]]> Tue, 5 Jun 2007 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200706/1131057_5_6.html Crucell N.V. <![CDATA[Crucell announces resignations of Supervisory Board members, Dr. Jürg Witmer and Dr. Claude Thomann]]> Fri, 1 Jun 2007 17:23:07 +0200 http://cws.huginonline.com/C/132631/PR/200706/1130668_5_6.html Crucell N.V. <![CDATA[Crucell announces live webcast of Annual General Meeting of Shareholders ]]> Wed, 30 May 2007 14:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200705/1129752_5_6.html Crucell N.V. <![CDATA[Crucell, AERAS and SATVI Announce Start of Tuberculosis Vaccine Clinical Trial in South Africa six months after launching initial trial in the United States]]> Fri, 11 May 2007 14:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200705/1126317_5_6.html Crucell N.V. <![CDATA[Crucell Announces First Quarter 2007 Results]]> Wed, 9 May 2007 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200705/1125254_5_6.html Crucell N.V. <![CDATA[Crucell CFO to present at Rodman & Renshaw Conference in Monaco]]> Tue, 8 May 2007 14:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200705/1125036_5_6.html Crucell N.V. <![CDATA[Crucell Announces PER.C6® Licensing Agreement]]> Fri, 27 Apr 2007 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200704/1122372_5_6.html Crucell N.V. <![CDATA[Crucell to Release Q1 2007 Earnings on Wednesday, May 9, 2007]]> Thu, 26 Apr 2007 14:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200704/1122248_5_6.html Crucell N.V. <![CDATA[Crucell celebrates 10th anniversary of Inflexal® V]]> Thu, 26 Apr 2007 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200704/1121813_5_6.html Crucell N.V. <![CDATA[Crucell broadens pandemic preparedness with grant awarded to develop H5N1 Influenza vaccine]]> Thu, 5 Apr 2007 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200704/1117158_5_6.html Crucell N.V. <![CDATA[Crucell Announces Start of Rabies Phase I Antibody Cocktail Clinical Study in India four months after launching initial US Trial]]> Wed, 4 Apr 2007 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200704/1116928_5_6.html Crucell N.V. <![CDATA[Crucell secures important patent covering influenza vaccine production]]> Tue, 3 Apr 2007 14:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200704/1116837_5_6.html Crucell N.V. <![CDATA[Crucell announces European protein distribution deal with Talecris Biotherapeutics]]> Tue, 3 Apr 2007 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200704/1116626_5_6.html Crucell N.V. <![CDATA[ DSM Biologics and Crucell Announce PER.C6® Licensing Deal with Taiwanese Development Center for Biotechnology]]> Mon, 26 Mar 2007 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200703/1114110_5_6.html Crucell N.V. <![CDATA[Crucell Announces Large Scale Quinvaxem(TM) Vaccinations in Ethiopia ]]> Fri, 23 Mar 2007 13:36:34 +0100 http://cws.huginonline.com/C/132631/PR/200703/1113779_5_6.html Crucell N.V. <![CDATA[Crucell announces influenza alliance with ADImmune Corporation]]> Thu, 22 Mar 2007 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200703/1113437_5_6.html Crucell N.V. <![CDATA[Crucell Announces PER.C6® Licensing Agreement with Pfizer Animal Health]]> Thu, 15 Mar 2007 14:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200703/1112092_5_6.html Crucell N.V. <![CDATA[Aeras commits further USD$5 million to existing TB research agreement with Crucell]]> Wed, 7 Mar 2007 14:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200703/1110167_5_6.html Crucell N.V. <![CDATA[DSM and Crucell announce breakthrough in the production of biopharmaceuticals with PER.C6® technology platform.]]> Wed, 14 Feb 2007 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200702/1104842_5_6.html Crucell N.V. <![CDATA[Crucell announces fourth quarter and annual results 2006]]> Tue, 13 Feb 2007 08:08:00 +0100 http://cws.huginonline.com/C/132631/PR/200702/1104561_5_6.html Crucell N.V. <![CDATA[Crucell and DSM intensify collaboration and development of PER.C6® human cell line]]> Thu, 8 Feb 2007 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200702/1103117_5_6.html Crucell N.V. <![CDATA[Crucell to Release 2006 Earnings on Tuesday, February 13, 2007]]> Wed, 31 Jan 2007 14:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200701/1100990_5_6.html Crucell N.V. <![CDATA[Crucell announces STAR(TM) Research License Agreement ]]> Wed, 31 Jan 2007 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200701/1100828_5_6.html Crucell N.V. <![CDATA[Crucell's PER.C6®-based West Nile Vaccine Demonstrates Excellent Safety and Tolerability ]]> Fri, 26 Jan 2007 14:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200701/1100188_5_6.html Crucell N.V. <![CDATA[Crucell awarded EU grant to develop malaria vaccine]]> Wed, 24 Jan 2007 08:13:45 +0100 http://cws.huginonline.com/C/132631/PR/200701/1099639_5_6.html Crucell N.V. <![CDATA[Crucell announces STAR(TM) Research License Agreement with Novo Nordisk A/S]]> Tue, 16 Jan 2007 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200701/1098229_5_6.html Crucell N.V. <![CDATA[Crucell and DSM Biologics announce PER.C6® license agreement with AbGenomics Corporation]]> Thu, 11 Jan 2007 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200701/1097609_5_6.html Crucell N.V. <![CDATA[DSM Biologics and Crucell Announce PER.C6® Licensing Agreement with Biotecnol SA for Antibody Production]]> Fri, 5 Jan 2007 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200701/1096671_5_6.html Crucell N.V. <![CDATA[Merck & Co., Inc. and Crucell Sign Cross-licensing Agreement on Vaccine Production Technology]]> Wed, 27 Dec 2006 11:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200612/1095281_5_6.html Crucell N.V. <![CDATA[Rhein Biotech shareholders approve merger with Crucell subsidiary]]> Fri, 22 Dec 2006 12:57:07 +0100 http://cws.huginonline.com/C/132631/PR/200612/1095089_5_6.html Crucell N.V. <![CDATA[Crucell subsidiary awarded EU grant to develop malaria vaccine]]> Fri, 22 Dec 2006 08:38:00 +0100 http://cws.huginonline.com/C/132631/PR/200612/1094990_5_6.html Crucell N.V. <![CDATA[Crucell and NIH Gain Approval and Move to Recruitment for Malaria Vaccine Clinical Study ]]> Tue, 19 Dec 2006 14:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200612/1094140_5_6.html Crucell N.V. <![CDATA[Crucell Reports First Orders For Contract Manufacturing Agreement with Wyeth Biotech ]]> Fri, 15 Dec 2006 14:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200612/1093608_5_6.html Crucell N.V. <![CDATA[Crucell Announces Start of Rabies Antibody Product Clinical Trial]]> Wed, 13 Dec 2006 14:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200612/1093061_5_6.html Crucell N.V. <![CDATA[Crucell Awarded an additional Quinvaxem(TM) Vaccine contract of over $20 Million for 2007 ]]> Fri, 8 Dec 2006 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200612/1092228_5_6.html Crucell N.V. <![CDATA[Crucell Awarded Contracts of Over $230 Million for Quinvaxem(TM) and Hepavax-Gene® Vaccines]]> Fri, 1 Dec 2006 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200612/1091049_5_6.html Crucell N.V. <![CDATA[Crucell Announces Completion of Acquisition of SBL Vaccin AB]]> Thu, 23 Nov 2006 11:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200611/1089791_5_6.html Crucell N.V. <![CDATA[Crucell Announces Acquisition of SBL Vaccin AB and Offering of New Ordinary Shares]]> Tue, 21 Nov 2006 11:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200611/1089281_5_6.html Crucell N.V. <![CDATA[Rhein Biotech N.V. to be delisted from Frankfurt stock exchange]]> Thu, 16 Nov 2006 19:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200611/1088764_5_6.html Crucell N.V. <![CDATA[Crucell Presents Update on Products and Programs at New York Analyst Meeting]]> Thu, 16 Nov 2006 11:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200611/1088680_5_6.html Crucell N.V. <![CDATA[Crucell Announces Third Quarter 2006 Results]]> Tue, 14 Nov 2006 08:03:32 +0100 http://cws.huginonline.com/C/132631/PR/200611/1088018_5_6.html Crucell N.V. <![CDATA[Crucell to Webcast Analyst Meeting on November 16, 2006]]> Thu, 9 Nov 2006 14:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200611/1087370_5_6.html Crucell N.V. <![CDATA[DSM and Crucell Celebrate Opening of PERCIVIA PER.C6® Development Center in Cambridge, Mass.]]> Wed, 8 Nov 2006 14:15:00 +0100 http://cws.huginonline.com/C/132631/PR/200611/1086991_5_6.html Crucell N.V. <![CDATA[The Netherlands Invest €18.4 Million to Develop Better Vaccines to Fight Raging TB Pandemic]]> Fri, 3 Nov 2006 15:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200611/1086133_5_6.html Crucell N.V. <![CDATA[Crucell to Release Q3 2006 Results on Tuesday, November 14, 2006]]> Tue, 31 Oct 2006 14:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200610/1084993_5_6.html Crucell N.V. <![CDATA[Crucell to Concentrate Research and Development in Leiden, The Netherlands]]> Mon, 30 Oct 2006 17:30:00 +0100 http://cws.huginonline.com/C/132631/PR/200610/1084795_5_6.html Crucell N.V. <![CDATA[Crucell and AERAS Announce Start of Tuberculosis Vaccine Clinical Trial]]> Wed, 25 Oct 2006 14:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200610/1083063_5_6.html Crucell N.V. <![CDATA[Crucell Announces Analyst Meeting on November 16, 2006]]> Wed, 18 Oct 2006 14:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200610/1081943_5_6.html Crucell N.V. <![CDATA[Crucell to Present at Sanders Morris Harris Middle Market Investor Growth Conference, New York, October 23]]> Wed, 18 Oct 2006 13:30:00 +0200 http://cws.huginonline.com/C/132631/PR/200610/1081935_5_6.html Crucell N.V. <![CDATA[Crucell Announces PER.C6® Commercial Licensing Agreement with ADImmune Corporation]]> Wed, 11 Oct 2006 14:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200610/1080566_5_6.html Crucell N.V. <![CDATA[Crucell Secures $16.2 million NIH Contract for HIV Vaccine Design and Development]]> Mon, 9 Oct 2006 14:53:00 +0200 http://cws.huginonline.com/C/132631/PR/200610/1080122_5_6.html Crucell N.V. <![CDATA[Crucell Announces Placement of First Module of New GMP Process Technology Center]]> Thu, 5 Oct 2006 07:30:00 +0200 http://cws.huginonline.com/C/132631/PR/200610/1079452_5_6.html Crucell N.V. <![CDATA[Crucell Announces Acquisition of Berna Products Corp. from Acambis]]> Mon, 2 Oct 2006 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200610/1078727_5_6.html Crucell N.V. <![CDATA[Crucell Announces WHO Prequalification for Quinvaxem(TM) Vaccine]]> Tue, 26 Sep 2006 11:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200609/1077562_5_6.html Crucell N.V. <![CDATA[Sanofi Pasteur PER.C6®-based Seasonal Influenza Vaccine Enters First Clinical Trial]]>
Preparedness Program
* Successful scale-up of PER.C6® to 20,000 liters]]> Tue, 26 Sep 2006 08:54:39 +0200 http://cws.huginonline.com/C/132631/PR/200609/1077658_5_6.html Crucell N.V. <![CDATA[Crucell and NIH VRC Announce Start of Ebola Vaccine Clinical Trial]]> Tue, 26 Sep 2006 08:16:04 +0200 http://cws.huginonline.com/C/132631/PR/200609/1077565_5_6.html Crucell N.V. <![CDATA[Crucell to Present at UBS Global Life Sciences Conference, New York, September 28]]> Wed, 20 Sep 2006 13:44:04 +0200 http://cws.huginonline.com/C/132631/PR/200609/1076805_5_6.html Crucell N.V. <![CDATA[Sanofi Pasteur Broadens Pandemic Preparedness With First Clinical Trial Of Novel PER.C6®-based H7N1 Vaccine]]> Tue, 19 Sep 2006 13:26:51 +0200 http://cws.huginonline.com/C/132631/PR/200609/1076538_5_6.html Crucell N.V. <![CDATA[Crucell Announces STAR(TM) Technology Research License Agreement]]> Thu, 14 Sep 2006 14:15:09 +0200 http://cws.huginonline.com/C/132631/PR/200609/1075395_5_6.html Crucell N.V. <![CDATA[Crucell Confirms Delisting of Berna Biotech]]> Fri, 8 Sep 2006 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200609/1074258_5_6.html Crucell N.V. <![CDATA[Crucell and UCB sign STAR(TM) License Agreement ]]> Thu, 7 Sep 2006 14:27:17 +0200 http://cws.huginonline.com/C/132631/PR/200609/1074195_5_6.html Crucell N.V. <![CDATA[Berna Biotech Ltd (SWX: BBIN) announces half-year results 2006]]> Tue, 29 Aug 2006 22:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200608/1072171_5_6.html Crucell N.V. <![CDATA[Crucell Announces Second Quarter 2006 Results]]> Tue, 29 Aug 2006 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200608/1071967_5_6.html Crucell N.V. <![CDATA[Crucell and DSM Biologics Announce Second PER.C6® Licensing Agreement with MorphoSys]]> Thu, 17 Aug 2006 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200608/1069549_5_6.html Crucell N.V. <![CDATA[Crucell to Release Q2 2006 Earnings on Tuesday, August 29, 2006]]> Tue, 15 Aug 2006 14:09:24 +0200 http://cws.huginonline.com/C/132631/PR/200608/1069251_5_6.html Crucell N.V. <![CDATA[Crucell Announces Suspension of Aerugen® Clinical Development]]> Tue, 18 Jul 2006 08:10:58 +0200 http://cws.huginonline.com/C/132631/PR/200607/1064252_5_6.html Crucell N.V. <![CDATA[Crucell and DSM Biologics Announce Invitrogen as First Partner in PER.C6® Vendor Network]]> Mon, 10 Jul 2006 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200607/1062461_5_6.html Crucell N.V. <![CDATA[DSM and Crucell Announce New CEO and Establishment of PER.C6® R&D Center in Boston Area]]> Wed, 28 Jun 2006 14:15:00 +0200 http://cws.huginonline.com/C/132631/PR/200606/1060504_5_6.html Crucell N.V. <![CDATA[Crucell Announces PER.C6® Licensing Agreement with Immuno-Biological Laboratories]]> Tue, 20 Jun 2006 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200606/1058263_5_6.html Crucell N.V. <![CDATA[Second Tokyo Infectious Diseases Forum Highlights Crucial Vaccine Initiatives to Fight the 'Big Three']]> Thu, 15 Jun 2006 10:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200606/1056885_5_6.html Crucell N.V. <![CDATA[Crucell to Present at Goldman Sachs Global Healthcare Conference, June 13, and Needham & Company Biotechnology and Medical Technology Conference, June 15]]> Thu, 8 Jun 2006 15:40:09 +0200 http://cws.huginonline.com/C/132631/PR/200606/1054585_5_6.html Crucell N.V. <![CDATA[Crucell Supervisory Board Chairman Mr Pieter Strijkert to Step Down; Succeeded by Mr Jan Oosterveld]]> Fri, 2 Jun 2006 08:05:00 +0200 http://cws.huginonline.com/C/132631/PR/200606/1053814_5_6.html Crucell N.V. <![CDATA[Crucell Announces Large Human Clinical Trial with Avian Influenza Vaccine]]> Wed, 31 May 2006 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200605/1053319_5_6.html Crucell N.V. <![CDATA[Crucell Announces First Quarter 2006 Results]]> Tue, 23 May 2006 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200605/1052356_5_6.html Crucell N.V. <![CDATA[Crucell Announces PER.C6® and ceNOS Licensing Agreements with BIOA&D]]> Mon, 22 May 2006 14:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200605/1052272_5_6.html Crucell N.V. <![CDATA[Crucell Announces PER.C6® Licensing Agreement with Upstate USA]]> Tue, 16 May 2006 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200605/1051267_5_6.html Crucell N.V. <![CDATA[Crucell Annual General Meeting of Shareholders to be Held in Leiden on June 2, 2006]]> Mon, 15 May 2006 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200605/1051011_5_6.html Crucell N.V. <![CDATA[Crucell to Release Q1 2006 Earnings on Tuesday, May 23]]> Tue, 9 May 2006 14:05:00 +0200 http://cws.huginonline.com/C/132631/PR/200605/1050057_5_6.html Crucell N.V. <![CDATA[Crucell Ends PER.C6® Patent Infringement Case as Final Demands are Satisfied]]> Tue, 9 May 2006 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200605/1049846_5_6.html Crucell N.V. <![CDATA[Crucell 2005 Annual Report Available Online]]> Fri, 28 Apr 2006 12:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200604/1047897_5_6.html Crucell N.V. <![CDATA[Crucell Presents Update on Strategy and Operations at Analyst Briefing]]> Thu, 27 Apr 2006 13:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200604/1047547_5_6.html Crucell N.V. <![CDATA[Crucell Analyst Briefing Update]]> Wed, 26 Apr 2006 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200604/1046766_5_6.html Crucell N.V. <![CDATA[Crucell to Webcast Analyst Day on April 27, 2006]]> Thu, 13 Apr 2006 14:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200604/1045187_5_6.html Crucell N.V. <![CDATA[Crucell Files for Cancellation of Remaining Berna Biotech Minority Shares]]> Wed, 12 Apr 2006 07:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200604/1044845_5_6.html Crucell N.V. <![CDATA[Crucell announces STAR(TM) Research License Agreement]]> Thu, 6 Apr 2006 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200604/1043654_5_6.html Crucell N.V. <![CDATA[Crucell to divest Gräub AG, the veterinary business of Berna Biotech]]> Wed, 5 Apr 2006 07:05:00 +0200 http://cws.huginonline.com/C/132631/PR/200604/1043334_5_6.html Crucell N.V. <![CDATA[Crucell Adopts IFRS as Primary Reporting Method and Announces 2006 Financial Calendar]]> Wed, 29 Mar 2006 17:30:00 +0200 http://cws.huginonline.com/C/132631/PR/200603/1041998_5_6.html Crucell N.V. <![CDATA[Crucell to sell Rhein Biotech GmbH to Dynavax]]> Mon, 27 Mar 2006 23:35:08 +0200 http://cws.huginonline.com/C/132631/PR/200603/1041492_5_6.html Crucell N.V. <![CDATA[Crucell Announces Product Approval in Korea for Quinvaxem(TM) Vaccine]]> Mon, 27 Mar 2006 07:52:02 +0200 http://cws.huginonline.com/C/132631/PR/200603/1041265_5_6.html Crucell N.V. <![CDATA[Crucell and DSM Biologics Announce PER.C6® Licensing Agreement with UCB]]> Tue, 14 Mar 2006 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200603/1038944_5_6.html Crucell N.V. <![CDATA[Crucell and DSM Biologics Announce PER.C6® Licensing Agreement with UMN Pharma]]> Thu, 9 Mar 2006 08:00:26 +0100 http://cws.huginonline.com/C/132631/PR/200603/1038392_5_6.html Crucell N.V. <![CDATA[First Trading Day of Crucell Shares on SWX Swiss Exchange]]> Wed, 22 Feb 2006 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200602/1035992_5_6.html Crucell N.V. <![CDATA[Crucell Announces 2005 Annual Results]]> Strong development and licensing activity drive 66% revenue increase for full year
  • Significant progress in all development programs
  • Net cash burn at low end of company guidance for 2005
  • Crucell and DSM partnership further strengthened
  • Successful public offer for Berna Biotech AG ]]> Tue, 24 Jan 2006 13:30:00 +0100 http://cws.huginonline.com/C/132631/PR/200601/1031074_5_6.html Crucell N.V. <![CDATA[Crucell and Ark Therapeutics Extend PER.C6® Agreement with Commercial License]]> Wed, 18 Jan 2006 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200601/1030279_5_6.html Crucell N.V. <![CDATA[Crucell to Release 2005 Earnings on Tuesday, January 24, 2006]]> Fri, 13 Jan 2006 14:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200601/1029870_5_6.html Crucell N.V. <![CDATA[Berna Shareholders Open Door for Combination with Crucell]]> Wed, 11 Jan 2006 19:15:15 +0100 http://cws.huginonline.com/C/132631/PR/200601/1029613_5_6.html Crucell N.V. <![CDATA[Crucell Shareholders Approve Exchange Offer for Berna Biotech]]> Tue, 10 Jan 2006 15:55:00 +0100 http://cws.huginonline.com/C/132631/PR/200601/1029419_5_6.html Crucell N.V. <![CDATA[Crucell Issues Trading Update]]> Tue, 10 Jan 2006 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200601/1029287_5_6.html Crucell N.V. <![CDATA[Crucell Licenses STAR(TM) Technology to XOMA for Research Use]]> Thu, 5 Jan 2006 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200601/1028743_5_6.html Crucell N.V. <![CDATA[Contract Manufacturing Agreement Takes PER.C6® into Canada]]> Thu, 22 Dec 2005 08:02:42 +0100 http://cws.huginonline.com/C/132631/PR/200512/1027096_5_6.html Crucell N.V. <![CDATA[Crucell Announces Second PER.C6® Licensing Agreement with Merial]]> Thu, 22 Dec 2005 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200512/1027088_5_6.html Crucell N.V. <![CDATA[Crucell and WRAIR Sign CRADA to Evaluate PER.C6® Technology for Development of Flavivirus Vaccines]]> Thu, 22 Dec 2005 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200512/1027041_5_6.html Crucell N.V. <![CDATA[Crucell and DSM Announce Second PER.C6® License Agreement with Ferring Pharmaceuticals]]> Wed, 21 Dec 2005 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200512/1026843_5_6.html Crucell N.V. <![CDATA[Crucell and DSM Announce PER.C6® Licensing Agreement with ZyStor Therapeutics]]> Wed, 21 Dec 2005 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200512/1026833_5_6.html Crucell N.V. <![CDATA[Crucell and DSM further strengthen and expand the development of PER.C6® Protein and Monoclonal Antibody Licensing Business]]> Tue, 20 Dec 2005 08:15:00 +0100 http://cws.huginonline.com/C/132631/PR/200512/1026562_5_6.html Crucell N.V. <![CDATA[Crucell Notes Berna Announcement of Due Diligence Request]]> Mon, 19 Dec 2005 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200512/1026297_5_6.html Crucell N.V. <![CDATA[Crucell Announces STAR(TM) Licensing Agreement with Genzyme]]> Mon, 19 Dec 2005 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200512/1026294_5_6.html Crucell N.V. <![CDATA[Crucell Gains Approval and Moves to Recruitment for West Nile Vaccine Phase I Clinical Study]]> Fri, 16 Dec 2005 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200512/1025926_5_6.html Crucell N.V. <![CDATA[Crucell Announces PER.C6® Licensing Agreement with Vakzine Projekt Management]]> Thu, 8 Dec 2005 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200512/1024603_5_6.html Crucell N.V. <![CDATA[Crucell Announces PER.C6® Licensing Agreement with Tibotec]]> Wed, 23 Nov 2005 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200511/1022503_5_6.html Crucell N.V. <![CDATA[Crucell Teams up with ACE BioSciences and Harvard to Accelerate Bacterial Antibody Program]]> Wed, 2 Nov 2005 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200511/1019118_5_6.html Crucell N.V. <![CDATA[Crucell to Present at Rodman & Renshaw Techvest 7th Annual Healthcare Conference, November 8]]> Tue, 1 Nov 2005 14:05:00 +0100 http://cws.huginonline.com/C/132631/PR/200511/1019079_5_6.html Crucell N.V. <![CDATA[Tokyo Infectious Diseases Forum Highlights Strategies to Combat Flu and Other Pandemics]]> Thu, 20 Oct 2005 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200510/1016821_5_6.html Crucell N.V. <![CDATA[Crucell and DSM Announce PER.C6® Licensing Agreement with IQ Corporation for Production of Monoclonal Antibodies against Anthrax]]> Wed, 19 Oct 2005 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200510/1016602_5_6.html Crucell N.V. <![CDATA[Crucell Announces Third Quarter 2005 Results]]> Mon, 17 Oct 2005 13:30:00 +0200 http://cws.huginonline.com/C/132631/PR/200510/1016298_5_6.html Crucell N.V. <![CDATA[Crucell Updates Progress in Scale-up of Cell-culture-based Influenza Vaccine Programs]]> Thu, 13 Oct 2005 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200510/1015285_5_6.html Crucell N.V. <![CDATA[Merck and Co., Inc. Exercises Option on PER.C6® License for Adenovirus-based Vaccine Against Hepatitis C]]> Mon, 10 Oct 2005 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200510/1014723_5_6.html Crucell N.V. <![CDATA[Crucell to Release Third Quarter Results on Monday, October 17]]> Mon, 3 Oct 2005 14:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200510/1014025_5_6.html Crucell N.V. <![CDATA[Crucell Files Financial Statements with Euronext for H1 2005 in Accordance with IFRS]]> Fri, 30 Sep 2005 15:15:00 +0200 http://cws.huginonline.com/C/132631/PR/200509/1013871_5_6.html Crucell N.V. <![CDATA[Crucell Clarifies CFO Comment Made at UBS Conference]]> Tue, 27 Sep 2005 16:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200509/1013384_5_6.html Crucell N.V. <![CDATA[Crucell to Present at UBS Global Life Sciences Conference, New York, September 26]]> Wed, 21 Sep 2005 14:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200509/1012637_5_6.html Crucell N.V. <![CDATA[Crucell Appoints Agents to Boost Asian Market Potential]]> Tue, 20 Sep 2005 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200509/1012391_5_6.html Crucell N.V. <![CDATA[Crucell Secures € 2 Million Grant from Dutch Ministry of Economic Affairs to Discover Antibodies Against Antibiotic-resistant Bacterial Infections]]> Fri, 16 Sep 2005 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200509/1012088_5_6.html Crucell N.V. <![CDATA[Crucell and Aeras Announce Progress in TB Vaccine Program]]> Thu, 8 Sep 2005 10:30:00 +0200 http://cws.huginonline.com/C/132631/PR/200509/1010908_5_6.html Crucell N.V. <![CDATA[Crucell and US Navy Sign Agreement to Test AdVac®-based Vaccine Against Anthrax and Plague]]> Wed, 17 Aug 2005 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200508/1006788_5_6.html Crucell N.V. <![CDATA[Crucell and DSM Announce PER.C6® Licensing Agreement with Chiron]]> Tue, 16 Aug 2005 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200508/1006433_5_6.html Crucell N.V. <![CDATA[Harvard and Crucell Receive $19.2 million NIH Grant to Develop Next-Generation AdVac®-based Vaccines]]> Mon, 1 Aug 2005 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200508/1004335_5_6.html Crucell N.V. <![CDATA[Crucell Announces Second Quarter 2005 Results]]> Mon, 18 Jul 2005 14:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200507/1002734_5_6.html Crucell N.V. <![CDATA[Crucell and DSM Announce PER.C6® Licensing Agreement with Symphogen for Polyclonal Antibody Protein Production]]> Fri, 15 Jul 2005 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200507/1002520_5_6.html Crucell N.V. <![CDATA[Crucell Announces Clinical Development of Human Monoclonal Antibody Combination Against Rabies]]> Thu, 14 Jul 2005 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200507/1002300_5_6.html Crucell N.V. <![CDATA[Crucell NV Options to be Listed on Euronext.liffe Amsterdam]]> Wed, 13 Jul 2005 17:45:00 +0200 http://cws.huginonline.com/C/132631/PR/200507/1002306_5_6.html Crucell N.V. <![CDATA[Crucell to Release Second Quarter Results on Monday, July 18]]> Tue, 5 Jul 2005 14:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200507/1001388_5_6.html Crucell N.V. <![CDATA[Fidelity Fund Acquires 5.13% Interest in Crucell]]> Tue, 28 Jun 2005 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200506/1000288_5_6.html Crucell N.V. <![CDATA[Human Monoclonal Antibody Against West Nile Virus Shows Promise in Animal Studies]]> Fri, 10 Jun 2005 14:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200506/998095_5_6.html Crucell N.V. <![CDATA[Crucell announces STAR(TM) arrangement with Medarex]]> Wed, 1 Jun 2005 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200506/996592_5_6.html Crucell N.V. <![CDATA[Crucell NV Options Listed on Chicago Board Options Exchange]]> Tue, 31 May 2005 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200505/996350_5_6.html Crucell N.V. <![CDATA[Crucell and DSM Announce PER.C6® License Agreement with Ferring Pharmaceuticals]]> Wed, 25 May 2005 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200505/995683_5_6.html Crucell N.V. <![CDATA[Crucell to Present at Needham & Company Fourth Annual Biotechnology Conference, May 26]]> Fri, 20 May 2005 18:07:10 +0200 http://cws.huginonline.com/C/132631/PR/200505/995329_5_6.html Crucell N.V. <![CDATA[Crucell Equity Offering Priced at € 14.50 per Share; € 52.2 Million Raised]]> Tue, 10 May 2005 18:30:00 +0200 http://cws.huginonline.com/C/132631/PR/200505/993712_5_6.html Crucell N.V. <![CDATA[Single-shot Outbreak Vaccine Provides Full Protection Against Ebola According to Results of New Animal Studies]]> Fri, 29 Apr 2005 08:00:25 +0200 http://cws.huginonline.com/C/132631/PR/200504/991972_5_6.html Crucell N.V. <![CDATA[Crucell to Present at Rodman & Renshaw 2nd Annual Global Healthcare Conference, May 4]]> Wed, 27 Apr 2005 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200504/991185_5_6.html Crucell N.V. <![CDATA[Crucell Announces First Quarter 2005 Results]]> Mon, 18 Apr 2005 14:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200504/989746_5_6.html Crucell N.V. <![CDATA[Crucell and NIH sign € 21.4 million Ebola Vaccine Manufacturing Contract]]> Thu, 14 Apr 2005 08:10:00 +0200 http://cws.huginonline.com/C/132631/PR/200504/989152_5_6.html Crucell N.V. <![CDATA[Crucell to Release First Quarter 2005 Earnings on Monday, April 18]]> Tue, 5 Apr 2005 14:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200504/987708_5_6.html Crucell N.V. <![CDATA[Crucell Receives US Patent Covering its STAR(TM) Technology]]> Tue, 5 Apr 2005 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200504/987619_5_6.html Crucell N.V. <![CDATA[Crucell's Cell-Culture Technology to Be Part of Major U.S. Government Influenza Pandemic Vaccine Program]]> Fri, 1 Apr 2005 17:22:10 +0200 http://cws.huginonline.com/C/132631/PR/200504/987370_5_6.html Crucell N.V. <![CDATA[ AFM Completes Investigation into Exercising of Options by Crucell Management]]> Fri, 1 Apr 2005 15:50:00 +0200 http://cws.huginonline.com/C/132631/PR/200504/987355_5_6.html Crucell N.V. <![CDATA[Crucell Announces PER.C6® Licensing Agreement with Vascular Biogenics]]> Wed, 30 Mar 2005 08:00:00 +0200 http://cws.huginonline.com/C/132631/PR/200503/986694_5_6.html Crucell N.V. <![CDATA[Crucell and DSM Announce PER.C6® Licensing Agreement with Mitsubishi Pharma for Protein Production]]> Wed, 23 Mar 2005 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200503/986234_5_6.html Crucell N.V. <![CDATA[Crucell Signs Commercial PER.C6® License Agreement with SingVax for Vaccines against Japanese Encephalitis]]> Tue, 22 Mar 2005 14:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200503/986144_5_6.html Crucell N.V. <![CDATA[ Crucell Secures Exclusive Patent License from NIH to Commercialize Ebola Vaccines]]> Fri, 18 Mar 2005 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200503/985601_5_6.html Crucell N.V. <![CDATA[Crucell and NIH extend Ebola Vaccine Agreement]]> Thu, 17 Mar 2005 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200503/985363_5_6.html Crucell N.V. <![CDATA[Crucell and DSM Announce PER.C6® Licensing Agreement with JCR Pharmaceuticals for Protein Production]]> Thu, 10 Mar 2005 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200503/984133_5_6.html Crucell N.V. <![CDATA[Galapagos is considering a stock exchange listing]]> Wed, 9 Mar 2005 09:28:50 +0100 http://cws.huginonline.com/C/132631/PR/200503/983872_5_6.html Crucell N.V. <![CDATA[Crucell and DSM Announce PER.C6® Licensing and Service Agreement with Roche for Protein Production]]> Wed, 16 Feb 2005 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200502/980896_5_6.html Crucell N.V. <![CDATA[Crucell Receives Patents Covering PER.C6® for Protein Production]]> Wed, 16 Feb 2005 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200502/980889_5_6.html Crucell N.V. <![CDATA[Crucell Confirms Selection for Amsterdam Midkap Index on Euronext]]> Mon, 31 Jan 2005 14:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200501/978069_5_6.html Crucell N.V. <![CDATA[Crucell Fully Compliant]]> Wed, 26 Jan 2005 13:32:36 +0100 http://cws.huginonline.com/C/132631/PR/200501/977548_5_6.html Crucell N.V. <![CDATA[Crucell Announces 2004 Annual Results]]> Mon, 24 Jan 2005 14:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200501/977103_5_6.html Crucell N.V. <![CDATA[Crucell Joins Influenza Vaccine Supply (IVS) International Task Force]]> Fri, 14 Jan 2005 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200501/975917_5_6.html Crucell N.V. <![CDATA[Crucell to Release 2004 Earnings on Monday, January 24, 2005]]> Mon, 10 Jan 2005 14:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200501/975387_5_6.html Crucell N.V. <![CDATA[Crucell Announces Evaluation by Genentech of STAR(TM) Technology]]> Fri, 7 Jan 2005 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200501/975172_5_6.html Crucell N.V. <![CDATA[Crucell Receives European Patent Covering PER.C6® for Vaccine Production]]> Wed, 5 Jan 2005 08:00:00 +0100 http://cws.huginonline.com/C/132631/PR/200501/974961_5_6.html Crucell N.V.